Abstract
Alzheimer disease (AD) is characterized by a progressive cognitive decline and accumulation of β-amyloid (Aβ) forming senile plaques that are associated with inflammatory molecules and cells. Resident microglia and newly differentiated cells that are derived from the bone marrow are found in the vicinity of Aβ plaques. Although these two types of microglia are not distinguishable by specific markers in the brain, they seem to possess different phenotype and functions. In mouse models of AD, bone marrow-derived microglia (BMDM) have been shown to delay or stop the progression of AD and preventing their recruitment exacerbates the pathology. Transplantation of competent hematopoietic stem cells or their genetic modifications ameliorate cognitive functions, reduce Aβ accumulation and prevent synaptic dysfunctions. Improving the recruitment of genetically-modified BMDM may be considered as a powerful new therapeutic strategy to counteract AD. Here we review the role of microglia subsets in AD and how these cells have a great potential to fight against Aβ accumulation and cognitive impairment.
Keywords: Microglia, Alzheimers disease, CCR2, CX3CR1, Inflammation, Innate immunity, Cytokines, Chemokines
Current Alzheimer Research
Title: The Role of Microglial Cell Subsets in Alzheimers Disease
Volume: 8 Issue: 2
Author(s): G. Naert and S. Rivest
Affiliation:
Keywords: Microglia, Alzheimers disease, CCR2, CX3CR1, Inflammation, Innate immunity, Cytokines, Chemokines
Abstract: Alzheimer disease (AD) is characterized by a progressive cognitive decline and accumulation of β-amyloid (Aβ) forming senile plaques that are associated with inflammatory molecules and cells. Resident microglia and newly differentiated cells that are derived from the bone marrow are found in the vicinity of Aβ plaques. Although these two types of microglia are not distinguishable by specific markers in the brain, they seem to possess different phenotype and functions. In mouse models of AD, bone marrow-derived microglia (BMDM) have been shown to delay or stop the progression of AD and preventing their recruitment exacerbates the pathology. Transplantation of competent hematopoietic stem cells or their genetic modifications ameliorate cognitive functions, reduce Aβ accumulation and prevent synaptic dysfunctions. Improving the recruitment of genetically-modified BMDM may be considered as a powerful new therapeutic strategy to counteract AD. Here we review the role of microglia subsets in AD and how these cells have a great potential to fight against Aβ accumulation and cognitive impairment.
Export Options
About this article
Cite this article as:
Naert G. and Rivest S., The Role of Microglial Cell Subsets in Alzheimers Disease, Current Alzheimer Research 2011; 8 (2) . https://dx.doi.org/10.2174/156720511795256035
DOI https://dx.doi.org/10.2174/156720511795256035 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Animal Models for Obsessive-Compulsive Disorder
Current Neuropharmacology Recent Trials for FTY720 (Fingolimod): A New Generation of Immunomodulators Structurally Similar to Sphingosine
Reviews on Recent Clinical Trials Editorial (Thematic Issue: Neuroglia as a Central Element of Neurological Diseases: An Underappreciated Target for Therapeutic Intervention)
Current Neuropharmacology Engineering of Chimeric Protein Based on E Protein Domain III of Tick- Borne Encephalitis Virus and OmpF Porin of Yersinia pseudotuberculosis
Protein & Peptide Letters Animal Models Used for the Evaluation of Antiretroviral Therapies
Current HIV Research Unexpected Altered Specificity Is Responsible for St. Louis Encephalitis Virus Recombinant Protease Autoproteolysis
Protein & Peptide Letters Non-IgE Mediated Food Allergy – Update of Recent Progress in Mucosal Immunity
Inflammation & Allergy - Drug Targets (Discontinued) Evaluation of the Effects of <i>Rumex obtusifolius</i> Seed and Leaf Extracts Against <i>Acanthamoeba</i>: An in vitro Study
Infectious Disorders - Drug Targets Glycine Rich P-loop Motif in Deoxyuridine Pyrophosphatase
Current Protein & Peptide Science The Genetic Basis of Human Cytomegalovirus Resistance and Current Trends in Antiviral Resistance Analysis
Infectious Disorders - Drug Targets Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology Mitochondrial Dysfunction in Huntington’s Disease: Pathogenesis and Therapeutic Opportunities
Current Drug Targets Endothelial Chemokines in Autoimmune Disease
Current Pharmaceutical Design Peptide Vaccine Models Using Statistical Data Mining
Protein & Peptide Letters Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology The Immune Response to the Parasitic Nematode Trichinella and the Ways to Escape it. From Experimental Studies to Implications for Human Infection.
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The p35 Family of Apoptosis Inhibitors
Current Genomics Therapeutic Options in Prevention and Treatment of Aspartoacylase Gene Mutation Resulting Abnormalities in Canavan Disease
Current Pharmacogenomics Astrocyte Infection by HIV-1: Mechanisms of Restricted Virus Replication, and Role in the Pathogenesis of HIV-1-Associated Dementia
Current HIV Research The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry